Rodrigo Almeida Toledo, PhD

Born in Sao Paulo (Brazil), January 22nd, 1979 (39 y-old)
Vall d´Hebron Institute of Oncoloy (VHIO)
Centro Cellex, Calle Natzaret, 115-117
08035 Barcelona, Spain
Tel: +34 932543450 ext: 8689
e-mail: rtoledo@vhio.net

Scientific Metrics

- H-index: **23**
- Peer-reviewed Scientific papers: **52**
- Total citations: **1.975**
- First author papers: **17**
  Last author papers: **6**

Summary

Rodrigo Toledo has a double graduation on Biological and Biomedical Sciences. He obtained his Masters in Science (2006) and PhD in Medical Genetics (2011) at the University of Sao Paulo School of Medicine and completed a 3-year postdoctoral fellowship at the University of Texas Health Science Center in San Antonio Texas, USA. In 2014, he joined the Spanish National Cancer Center (CNIO, Madrid) as staff researcher.

In 2017 he was **awarded the prestigious 5-year Miguel Servet grant** and the **Olga Torres Foundation award** and has become an **Emerging PI Researcher at the Vall d´Hebron Institute of Oncology in Barcelona (VHIO).**

Dr. Toledo is a **biomarker researcher and has been involved in the identification and functional characterization of multiple new cancer susceptibility genes as *TMEM127*, HIF2A/*EPAS1*, *MERTK* and *H3F3A***. In addition to his experience on genetics, genomics and functional characterization of cancer genes, in the last years he has been interested on developing predictive biomarkers and cancer immunotherapy for advanced cancer patients. Recently, Dr. Toledo discovered and functionally validated the *KDR*/VEGFR2 somatic mutations as the cause of resistance to anti-angiogenic treatments in patients withmetastatic disease.

Dr. Toledo is the **current Leader of the Liquid Biopsy & Biomarkers of the CIBERONC Spanish National Cancer Network.** CIBERONC comprises more than 650 basic, translational and clinical researchers.

Professional experience

Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain 2017- 2022 (contract)
Emerging researcher, leads a group of 3 people

Spanish National Cancer Center, Madrid, Spain 2014-2017
Translational Cancer Biology/Genomics researcher

University of Texas Health Science Center (UTHSCA), USA 2011-2014
Postdoctoral Research Fellow

Education

PhD, University of Sao Paulo School of Medicine, SP, Brazil	2007-2011
Masters, University of Sao Paulo School of Medicine, SP, Brazil	2004-2006
Biomedicine, University of Sao Paulo, SP, Brazil	2006-2010
Biology, University of Sao Paulo, SP, Brazil	2000-2004

Language skills English, Portuguese, Castellano: fluent

PI's selected publications - **Average Journals' Impact factor: 22,7**

1: **Toledo RA;** NGS in PPGL (NGSnPPGL) Study Group. Inflated pathogenic variant profiles in the ClinVar database. ***Nat Rev Endocrinol. (2018)***
Impact factor: **18,3**
2: Vaidya A *et al.*, EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease. ***New England Journal of Medicine (2018)***
Impact factor: **72,4**
3: Toledo RA *et al.*, Exome sequencing of plasma DNA portrays the mutation landscape of colorectal cancer and discovers mutated VEGFR2 receptors as modulators of anti-angiogenic therapies.
Clinical Cancer Research (2018)
Impact factor: **9,6**
4: **Toledo RA** *et al.*, Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas.
Nature Reviews Endocrinology (2017) Impact factor: **18,3**
Citations: 33
5: **Toledo RA** *et al.*, Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas.
Clinical Cancer Research (2016)
Impact factor: **9,6**
Citations: 36
6: Castinetti F *et al.*, Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international

retrospective population-based study.
Lancet Oncology (2014)
Impact factor: **33,9**
Citations: 59
7: **Toledo RA** *et al.*, In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.
Endocrine Related Cancer (2013)
Impact factor: **5,2**
Citations: 66
8: Agrawal N *et al.*, Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.
Journal Clinical Endocrinology & Metabolism (2013)
Impact factor: **5,4**
Citations: 126
9: Yao L *et al.*, Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas.
Journal of the American Medical Association (JAMA) (2010)
Impact factor: **44,4**
Citations: 152
10: Qin Y *et al.*, Germline mutations in TMEM127 confer susceptibility to pheochromocytoma.
Nature Genetics (2010)
Impact factor: **27,9**
Citations: 314
11: **Toledo RA** *et al.*, Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma.
Journal Clinical Endocrinology & Metabolism (2007)
Impact factor: **5,4**
Citations: 83